Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …

Objectives To update and assess the efficacy and tolerability of once weekly subcutaneous
semaglutide in patients with type 2 diabetes (T2D). Materials and methods PubMed, Science …

Objectives To investigate the safety and efficacy of once-weekly glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide as monotherapy or add-on to other …

Introduction The efficacy of once-weekly (OW) semaglutide for the treatment of type 2
diabetes mellitus (T2DM) has been demonstrated in clinical trials. The aim of this systematic …

Introduction: Type 2 diabetes is a chronic metabolic disease characterized by persistent
hyperglycemia resulting from progressive deficient of insulin in patients with a background of …

Aims To assess the efficacy and safety of semaglutide, a recently approved glucagon‐like
peptide 1 receptor agonist (GLP‐1 RA) for type 2 diabetes. Materials and methods We …

Background: This meta-analysis aimed to combine the data available from clinical trials to
assess the effects of subcutaneous and oral semaglutide administration on glycemic control …

Objectives To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only
orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 …

Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study,
investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine …

Objectives To evaluate the efficacy and safety of the glucagon-like peptide-1 (GLP-1)
receptor agonist (RA) oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) …